MYOK - Myriad's Ovarian Cancer Test Approved And Other News: The Good Bad And Ugly Of Biopharma
Myriad Receives the FDA Approval for Testing Ovarian Cancer
Myriad Genetics (MYGN) announced that the FDA has given green signal to its myChoice CDx test to be used as a companion diagnostic for the identification of advanced ovarian cancer patients. The company stated that the device is one of the most comprehensive HRD tests and recognizes people with tumors that are no longer able to repair double stranded DNA breaks. This development leads to higher vulnerability to drugs such as PARP inhibitors which have the potential to damage the DNA.
This test is